Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial

Key Points

• Ivarmacitinib significantly enhances quality of life in patients with moderate-to-severe atopic dermatitis, and improves sleep quality.
• The post hoc analysis from a phase III trial indicated improvements in working productivity among those treated with ivarmacitinib.
• Phase III trial data highlighted the effectiveness of ivarmacitinib as a selective Janus kinase-1 inhibitor for atopic dermatitis.
• Findings suggest that ivarmacitinib may offer substantial benefits beyond itch relief, impacting daily activities and overall well-being.